Shares of Zymeworks were higher after the Food and Drug Administration cleared the company's investigational new drug application for its treatment for liver cancer. The stock rose 8.5%, to $14.46, in ...

The FDA accepted a resubmitted new drug application for reproxalap, a first-in-class investigational topical therapy for dry ...

After losing 3,500 employees in April—19% of its workforce due to congressional budget cuts—the FDA is now struggling to meet ...

Second antibody-drug conjugate (ADC) to progress into clinical development utilizing our proprietary payload and optimized antibodyPreclinical results demonstrate strong anti-tumor activity and favora ...

Submission of NDA for LNZ100 in China by CORXEL Pharmaceuticals results in achievement of first milestone due to LENZ under the Development and Commercialization Agreement ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a California-based company specializing in cortisol modulation through ...

LENZ Therapeutics previously licensed Greater China rights to CORXEL for the development and commercialization of LNZ100 in April 2022.

For example, a cancer patient can now buy a locally produced immunity boosting drug for Tk 7,000-8,000 per pre-filled syringe, while the imported version would cost Tk 85,000-95,000. Experts note that ...

GoodRx reports that in 2025, novel drug and biosimilar approvals lag slightly behind last year, while first generic approvals ...

Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque ...

The Supreme Court’s recent unanimous decision on FDA’s tobacco-authorization authority is utterly unremarkable.

Researchers at the National University of Singapore (NUS) have found new applications of magnetic field therapy with ...